17 August 2020: Clinical Research
Evaluation of Ovarian Tumors with Multidetector Computed Tomography and Tumor Markers: Differentiation of Stage I Serous Borderline Tumors and Stage I Serous Malignant Tumors Presenting as Solid-Cystic Mass
Xin-Ping Yu 1BCE , Ying Liu 2C , Jin-Wen Jiao 1D , Hong-Juan Yang 1B , Rui-Jing Wang 1D , Shuai Zhang 3ACF*DOI: 10.12659/MSM.924497
Med Sci Monit 2020; 26:e924497
Table 4 Predicting SMOTs by multivariate analysis of age, tumor markers and MDCT features.
| Parameter | Crude OR | P value | Adjusted OR | P value |
|---|---|---|---|---|
| Age (years) | 1.098 (1.051–1.148) | 1.089 (1018–1.166) | 0.014 | |
| CA125 (U/mL) | 1.002 (1.000–1.003) | 0.007 | 1.001 (0.999–1.003) | 0.382 |
| HE4 (pmol/L) | 1.015 (1.006–1.024) | 0.001 | 1.008 (0.996–1.021) | 0.182 |
| Texture | 7.000 (2.866–17.094) | 2.994 (0.770–11.642) | 0.114 | |
| Vascular abnormalities | 10.000 (3.880–25.773) | 11.12 (2.697–45.835) | 0.001 | |
| Maximum thickness of wall (mm) | 2.339 (1.430–3.823) | 0.001 | 1.654 (0.762–1.654) | 0.203 |
| Maximum thickness of septa (mm) | 1.979 (1.232–3.179) | 0.005 | 1.545 (0.700–3.411) | 0.282 |
| Maximum diameter of solid component (mm) | 1.104 (1.056–1.154) | 1.069 (1.010–1.146) | 0.045 | |
| SMOTs – serous malignant ovarian tumors; MDCT – multidetector computed tomography; OR – odds ratio; CA125 – serum cancer antigen 125; HE4 – human epididymis protein 4. | ||||